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The Plasmodium falciparum Pfs230 and Pfs48/45 proteins are expressed during
transmission fromman tomosquito and are leading candidates for a malaria transmission
blocking vaccine. Individually they generate transmission blocking (TB) antibodies in
rodent models. Whether the single protein vaccines are suitable to use in field settings will
primarily depend on their potency to elicit functional antibodies. We hypothesized that a
combination of both proteins will be more potent than each protein individually. Therefore
we designed chimeric proteins composed of fragments of both Pfs230 and Pfs48/45
as well as single protein fragments, and expressed these in Lactoccus lactis. Both the
individual Pfs230 and Pfs48/45 fragments and chimeras elicited high levels of functional
antibodies in mice. Importantly, one of the chimeric proteins elicited over threefold higher
transmission blocking antibody responses than the single antigens alone. Furthermore
the immunogenicity of one of the chimeras could be enhanced through coupling to a
virus-like particle (VLP). Altogether these data support further clinical development of
these novel constructs.
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INTRODUCTION
The transmission of Plasmodium falciparum from one person to another relies on the generation
of male and female gametocytes in the human host that can be picked up and spread by a
mosquito. The aim of a malaria transmission blocking vaccine (MTBV) is to effectively block
malaria transmission at the population level thereby contributing to malaria elimination.
Several MTBV candidates have been identified by screening monoclonal antibodies generated
against P. falciparum mosquito stages for TB activity (1–4). Three proteins, Pf s48/45, Pf s230, and
Pf s25 are currently targeted as lead candidates for an MTBV. Of these, Pf s48/45 and Pf s230 are
expressed in the gametocyte as it develops from stage III through V in the human host. Shortly,
after being taken up by a blood-feeding mosquito, the parasite emerges from the RBC as a gamete
and after a few rounds of replicationmotile males fertilize female gametes to form zygotes. Pf s48/45
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is expressed on the surface of both male and female gametes
where it is bound to the plasmamembrane through a GPI-anchor
(5) and forms a stable complex with Pf s230 (6). Both Pf s48/45
and Pf s230 are important for male fertility (7).
Humans develop naturally acquired immunity against P.
falciparum gametocytes (8–10) and antibodies against Pf s230
and Pf s48/45 have been associated with TB activity in some
but not all immune epidemiological studies (11, 12). Recently,
we demonstrated that Pf s48/45- and Pf s230-specific antibodies
exhibit strong TB activity in the standard membrane feeding
assay (SMFA) (13), the gold standard for assessing transmission
blockade ex vivo (2, 14–16). Whether such antibodies act
synergistically, as observed for combinations of mAbs targeting
different epitopes on Pf s48/45 (2), is not yet known.
Pf s48/45 and Pf s230 are members of the six-cysteine (6-
Cys) s48/45 protein family and contain three and fourteen 6-Cys
domains respectively (17). Each 6-Cys domain contains up to
six cysteine residues that are involved in intra-domain disulfide
bond formation which results in conformational antibody
epitopes. The C-terminal 6-Cys domain of Pfs48/45 contains the
conformational epitope I, which is targeted by the most potent
TB monoclonal antibody described to date, mAb45.1 (18). We
have recently used the Lactococcus lactis expression system for
the production of the C-terminal 6-Cys domain of Pf s48/45
(6C) as a fusion protein (R0.6C) with the N-terminal GLURP-R0
region (19, 20). The resulting fusion protein can be produced in
high yields of properly folded monomeric protein which elicited
high levels of TB antibodies in small rodents (19, 20). In the
case of Pf s230, the C fragment spanning the N-terminal pro-
domain and first three 6-Cys domains has been shown to elicit
the most potent TB antibodies (21). The presence of three 6-
Cys domains suggests that disulfide bonds may be critical for
proper folding of each of these domains. Accordingly, a series
of Pf s230-specific transmission-blocking monoclonal antibodies
did not recognize reduced Pf s230 (22). In an attempt to identify
the minimal Pf s230-domain involved in the generation of
TB antibodies, Pf s230 constructs containing the Pro, Pro+I,
Pro+I,II, and Pro+I,II,III domains were produced individually
in the wheat germ cell-free system (23). Interestingly, the N-
terminal Pro domain, which lacks cysteines, was sufficient to elicit
complement-dependent TB activity in the SMFA, suggesting that
TB antibodies may also be directed against non-conformational
epitopes (23). With respect to Pf s230, the C-fragment was the
first construct to elicit TB antibodies; however, oocyst reduction
was incomplete suggesting that folding was compromised by
an incorrect cysteine connectivity (21). Another construct,
Pf s230D1, corresponding to amino acid residues 444 to 736 was
produced in Pichia pastoris as a properly folded protein and
elicited TB antibodies in rodents (24).
While clinical trials with Pf s230D1 are ongoing
(ClinicalTrials.gov Identifier: NCT02334462) and R0.6C is
in early clinical development phase, we sought to identify
more potent Pf s48/45- and Pf s230-based immunogens.
We hypothesized that a combination of antibodies against
both proteins would be more potent than against each
antigen individually. Therefore we constructed chimeric
proteins composed of fragments of both Pf s230 and Pf s48/45,
expressed these in L. lactis and evaluated antibody responses
in rodents. A multicomponent hybrid protein containing both
Pf s48/45 and Pf s230 holds the potential to lower the required
threshold of functional antibodies and to reduce the risk of
escape mutations.
METHODS
Preparation of Constructs
Three different truncated forms of Pf s230 from N-terminus, i.e.
Pro (pro domainAA 443 to 590), Pro+I (pro domain and domain
I, AA 443 to 736) and Pro+I,II,III (pro domain through domain
III, AA 443 to 1132) were amplified by PCR from P. falciparum
3D7 DNA (GenBank accession number L08135) and cloned into
the BglII restriction site of pSS5 plasmid containing N-terminus
Spycatcher (25). Pf s48/45291−428 (6C) was amplified from an
expression vector encoding R0.6C (19, 20) using the forward
primer 5′-CCATGGATCCGAAAAAAAAGTCATACACGGA
TGTAACTTC-3′ and the reverse primer 5′-CCATAGATCTT
GCTGAATCTATAGTAACTGTCATATAAGC-3′. The amplified
PCR product was digested with BamHI and BglII (underlined)
and cloned in frame into plasmids containing the Pro or Pro+I
inserts to generate Pro-6C and Pro+I-6C fusion constructs,
respectively. All the constructs were verified by DNA sequencing
and transformed into L. lactis MG1363 by electroporation for
expression of recombinant proteins with 6xHis tags.
Fermentation and Protein Purification
Fermentation of L. lactisMG1363, containing Pf s230 or Pf s230-
Pf s48/45 fusion constructs were carried out as described
previously (19, 26). Briefly, cell-free culture-filtrates were
concentrated five-fold and buffer exchanged into Tris buffer
(50mM Tris, 50mM NaCl pH 8.0 supplemented with 10mM
Imidazole) using a Quix Stand Benchtop system (Hollow fiber
cartridge with cutoff at 10,000 or 30,000 Da, surface area
650cm2, GE Healthcare, Sweden) followed by filtration through
a Durapore filter (PVDF, 0.22µm, Millipore) and applied to
a 5ml HisTrap HP column (GE Healthcare, Sweden). Bound
protein was eluted with 500mM Imidazole in Tris buffer pH
8.0 (50mM Tris, 50mM NaCl) at a flow rate of 4 ml/min.
Fractions containing the desired protein were further applied
to a 5ml HiTrap Q HP column (GE Healthcare, Sweden) for
purification of monomeric proteins. Bound protein was eluted
through step gradient elution in Tris buffer pH 8.0 (50mM Tris,
1mM EDTA, 1M NaCl) and fractions containing monomers
were concentrated by a VIVA spin column with a 10 or 30 kDa
cutoff (Vivascience, Germany), and kept in 50mM Tris, 250mM
NaCl and 1mM EDTA, pH 8.0 at −80◦C until use. Immune
purification for Pro-6C and Pro+I-6C was done as previously
described (26). Fractions containing the desired protein were
pooled and then concentrated and buffer exchanged against
50mM Tris, 100mM NaCl, and 1mM EDTA, pH 8.0 and kept
at −80◦C until use. Fractions were analyzed by SDS-PAGE and
immune blotting with mAb45.1 against Pf s48/45 conformational
epitope I. Protein concentrations were measured using a BCA kit
(Thermo Fisher Scientific, USA).
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Protein Characterization
Analytical size exclusion high-performance liquid
chromatography (SE-HPLC) of purified fusion proteins
was performed as described previously (19, 20). Briefly, 5 µl
of protein was loaded on an Agilent advance Bio SEC 300 Å,
2.7µm, 4.6 × 300mm SEC column (Agilent Technologies, GB)
and eluted with a 0.1 ml/min flow of elution buffer (phosphate
buffer) at room temperature. Protein standards (Sigma Aldrich)
were also run using the same conditions mentioned above for
sizing of the purified recombinant proteins. The amount of free
cysteine residues was measured using Ellman’s Reagent (Thermo
Fisher Scientific, USA) following the manufacturer’s instructions.
A standard curve was constructed using known concentrations
of free cysteine (Sigma-Aldrich, USA). Folding was determined
in the mAb45.1 sandwich ELISA as described (19, 26).
Production of VLPs
SpyTag was genetically fused to the N-terminus of AP205, as
previously described (27). In brief, the SpyTag peptide sequence
(AHIVMVDAYKPTK) was fused to the gene sequence encoding
the major AP205 coat protein (Gene ID: 956335) using a
flexible linker (GSGTAGGGSGS) between the two sequences.
The SpyTag-AP205 VLPs were expressed in Escherichia coli One
Shot R© BL21 StarTM (DE3) cells (Thermo Fisher Scientific, USA)
and purified by ultracentrifugation using an OptiprepTM (Sigma-
Aldrich, USA) gradient. For conjugation to VLPs, purified
soluble Pro-6C or Pro+I-6C proteins were incubated at a molar
ratio of 1:1 (VLP/antigen) in a 1xPBS buffer for 2 h at room
temperature. Unbound protein was removed by dialysis against
PBS using 1,000 MWCO dialysis tubing (Spectrum Labs, USA).
Densitometric analysis of SDS-PAGE gels was used to estimate
protein concentrations.
Dynamic Light Scattering
Uncoupled VLP, soluble proteins and proteins conjugated to VLP
were adjusted to 0.5–1 mg/ml in PBS and spun at 15,000 g for
10min. Seventy Microliter sample was loaded into a disposable
Eppendorf Uvette cuvette (Sigma-Aldrich, USA) and measured
at 25◦C on a DynoPro NanoStar (WYATT Technology, USA)
equipped with a 658 nm laser. Each sample was measured 20
times and intensity-average size and percentage polydispersity
(PD) was estimated using Dynamic software (Version 7.5.0).
Electron Microscopy
Pro-6C or Pro+I-6C coupled to VLP (with concentrations
between 0.4 and 0.5 mg/ml based on antigen content) were
incubated on carbon-coated and glow-discharged grids and
negatively stained with 2% phosphotungstic acid (pH 7.4).
The particles were analyzed on a CM 100 BioTWIN electron
microscope with an accelerating voltage of 80 kV. Images were
acquired using an Olympus Veleta camera and particle size was
estimated using iTEM software.
Animals and Immunogenicity Studies
In the first experiment, groups (n = 5) of CD-1 mice 5–7
weeks of age (Janvier Labs, Denmark) were immunized 3 times
at 3-week interval by the intramuscular injection of equimolar
amounts of immune-purified Pro-6C and the individual Pf s230
and Pfs48/45 recombinant protein constructs formulated with
Alhydrogel R© (Brenntag, Denmark) to a final concentration of 2
mg/ml Aluminum. Please note that six mice received R0.6C. Each
dose contained 128 pmoles of soluble protein (equivalent to 2 µg
6C). Serum was collected on days 14, 35, and 56. In the second
experiment, groups (n = 8) of CD-1 mice were immunized
with 64 pmoles (equivalent to 1 µg 6C) Pro-6C or Pro+I-
6C (soluble or conjugated to VLP) as described above for the
first experiment. One mouse receiving Pro+I-6C was terminated
due to behavioral abnormalities not related to vaccination. All
animals were treated in accordance with the regulations and
guidelines of the European and National authorities.
Enzyme-Linked Immunosorbent Assay
(ELISA) for Antibody Response
Measurement
Gametocyte extract ELISA was performed with cultured
sexual stage of Pf NF54 parasites as previously described (26).
Serum immunoglobulin (IgG) subclass levels were measured
using ELISA as previously described (28). For antigen-specific
ELISA, 96-well plates (Nunc MaxiSorp) were coated with
0.5 µg/well of Pf s48/45-6C (25), Pro+I, or Pro+I,II,II as
appropriate. Antigen-specific antibodies were detected using
HRP-conjugated polyclonal goat anti-mouse IgG (Novex
A16072, diluted 1:3000). Antibody midpoint titer (EC50) was
calculated using sigmoidal curve fitting. One-sided analysis of
variance on the log-transformed values was used to confirm
that ELISA data contain essential differences. Mann-Whitney
test was then used to investigate whether the chimera elicited
higher levels of specific antibodies compared to individual
components. p-Values are two-sided and quoted without
adjustment for multiple testing since the significance of
the chimera was the primary problem under investigation.
p-values ≤ 0.05 were considered significant. Statistical
analysis was conducted using GraphPad Prism 7 (GraphPad
Software, USA).
Standard Membrane Feeding Assay (SMFA)
The biological activity of specific antisera was assessed in the
SMFA as previously described (26, 29). Depending on availability,
wild type P. falciparum NF54 gametocytes or transgenic P.
falciparumNF54 (NF54-HGL) gametocytes expressing luciferase
(29) were fed to Anopheles stephensi mosquitoes that were
reared and maintained at Radboudumc, The Netherlands.
Non-heat inactivated mice sera, and active or heat-inactivated
human complement was added to the cultured material
prior to feeding to mosquitoes. After 6–8 days, oocysts
in 20 fed mosquitoes were counted by microscopy, or
quantified in four pools of five mosquitoes (NF54-HGL)
by measuring luciferase levels (29). Samples were tested in
two independent SMFA experiments. Luminescence-based TRA
estimates from two independent feeds with each of four
pools of five mosquitoes were made using generalized linear
mixed models (GLMMs) without zero-inflated negative binomial
error structure (30, 31). Microscopy-based estimates from two
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feeds with 20 mosquitoes each were made using GLMMs
with zero-inflated negative binomial error structure (30, 31).
Statistical differences between test samples were determined
using General Linear Mixed Regression analysis. Statistical
analyses were performed using R studio (v. 3.2.4, The R
Foundation, Boston, USA). Pre-immune pooled mice serum
samples were also tested in a single independent SMFA
experiment (Figure S2).
Depletion of Antigen-Specific IgGs
Pf s230- and Pf s48/45-specific antibodies were depleted
from serum using Pf s230-CMB (32) and R0.10C-containing
columns respectively, as previously described (13). The
Pf s230-CMB fragment contains AA 444-730 and thus
covers the Pro+I fragment expressed in L. lactis. To
test if all antigen-specific IgGs were depleted, the flow
through serum (depleted serum) was tested in ELISA using
plates coated with Pf s230-CMB or SpyC-6C as appropriate
(25, 26).
RESULTS
Expression of a Multivalent
Pfs230-Pfs48/45 Chimera in L. Lactis
To test whether a multivalent vaccine targeting Pf s48/45 and
Pf s230 is immunogenic, we generated a chimeric construct
containing the Pro domain of Pf s230 fused to the 6C
fragment of Pf s48/45 (Figure 1A). We anticipated that this
Pro-6C fusion protein would express well in L. lactis since
the Pf s230-Pro domain is glutamate-rich, does not contain
cysteines, and is similar to the R0 domain which previously
enhanced expression of properly-folded 6C in L. lactis (25,
26). In addition to Pro-6C, we made constructs that either
contained Pf s48/45 or Pf s230 fragments (Figure 1A). L. lactis
MG1363 harboring these constructs were grown in a 1L
bioreactor and the respective recombinant proteins were purified
from the clarified supernatant through the C-terminal His-
tag by immobilized metal affinity chromatography and ion
exchange chromatography (Figure 1B). As expected, protein
yields decreased with increasing number of Pf s230 domains
FIGURE 1 | Production of recombinant Pfs230 and Pfs48/45. (A) Schematic representation of Pfs230 constructs and Pfs230-Pfs48/45 chimera. Each construct
contains the SpyCatcher sequence at the N-terminus and a His-tag at the C-terminus. 6-Cys domains are shown as boxes and numbers indicate the number of
cysteines. The Pro-domain does not contain cysteines. (B) Coomassie blue stained 4–12.5% polyacrylamide gel of conventionally purified Pfs230 constructs and
immune-purified Pro-6C chimera. Protein was loaded in each lane with (+) or without (–) DTT (10mM). The sizes (kDa) of the molecular mass markers are indicated.
(C) Sandwich ELISA of purified Pro-6C chimera. The antigens were captured with mAb45.1 and detected with anti-His-HRP. Immune purified R0.6C were used as a
reference. X-axis is shown on a logarithmic scale.
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(Table S1). Pro-6C was further immune-purified on a mAb 45.1-
column to enrich for properly folded protein species (Figure 1B).
The yield of immune-purified Pro-6C was 15mg/L, similar to
that of R0.6C. Conformational mAb 45.1 against the Pf s48/45
epitope I reacted with Pro-6C and this binding was equivalent
to that of immune-purified R0.6C, suggesting that they exhibit
similar cysteine-connectivity (Figure 1C).
Immunogenicity of Soluble Pfs48/45 and
Pfs230 Protein Constructs
Groups of mice were immunized 3 times at 3-week interval
with equimolar amounts of Pro-6C and individual Pf s230
and Pf s48/45 recombinant protein constructs formulated
on Alhydrogel R©. We used a suboptimal antigen dose to
detect differences in immunogenic properties between protein
constructs. Chimeric Pro-6C elicited significantly higher levels
of gametocyte-specific antibodies than those obtained with the
individual Pro domain (Mann-Whitney test, p = 0.0079) and
levels comparable to those obtained with Pro+I, and R0.6C
(Figure 2A). We found that levels of specific antibodies against
the Pro and 6C domains were similar in mice immunized with
Pro-6C compared to mice immunized with the individual Pro
and 6C (R0.6C) antigens, suggesting that these domains do not
exhibit antigenic competition (Figures 2B,C). As expected, levels
of Pf s230-specific antibodies increased with Pf s230 fragment
length (Figure 2C). The functional activity of vaccine-induced
antibodies was determined by testing pooled antisera from each
group in serial dilutions in the SMFA. All proteins except
the Pro domain, elicited a TB response of >80% at a 1/9
dilution. Interestingly, Pro-6C induced higher levels of functional
FIGURE 2 | Immunogenicity of Pro-6C and individual fragments. Groups of mice (n = 5) were immunized with immune purified Pro-6C in a comparative study with
individual Pro, Pro+I, Pro+I,II,III and R0.6C constructs. Day 56 serum was tested for antibody reactivity on ELISA plates coated with (A) gametocyte extract,
(B) Pfs48/45-6C or (C) Pfs230 Pro+I,II,III. Antibody titers (dots represent individual mice) are expressed as EC50 values. Horizontal lines represent median values.
The asterisks represent statistical significance determined by Mann-Whitney test (**p < 0.01, ns not significant). (D) Functional activity of serial dilutions of pooled sera
in the SMFA. Transmission reducing activity (TRA) is the reduction of oocyst numbers compared to a serum control. All samples were tested in the presence of active
complement. Data points are best estimates of two independent SMFA experiments and error bars represent 95% confidence intervals. Comparison between test
samples was done using General Linear Mixed Regression analysis (***p < 0.005, ns, not significant).
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antibodies than the other recombinant proteins including R0.6C
(p < 0.001) (Figure 2D), supporting further investigation of
multi-component Pf s230-Pf s48/45 vaccines.
Generation of Soluble and VLP-Based
Chimeric Constructs
Next, we tested whether the potency of Pro-6C could be
further increased by including the first 6-Cys domain of
Pf s230 (Pro+I-6C) (Figure 3A). The Pro+I-6C chimera was
purified following the same workflow developed for Pro-6C.
The yield of immune-purified Pro+I-6C was 5 mg/L, which
was 3-fold lower than that of Pro-6C most likely due to the
additional cysteine residues (Table S1). The folding of both
chimera was similar as determined in the mAb45.1 sandwich
ELISA (Figure 3B). Disulfide-bonding was confirmed by
demonstrating very low levels of free thiol groups (<1%)
under native conditions (data not shown). Immune purified
Pro-6C and Pro+I-6C eluted as single peaks by analytical
size exclusion chromatography demonstrating that they
form homogeneous solutions of monomeric protein species
(Figures 3C,D). Before starting in vivo immunogenicity studies
with both soluble constructs, we also coupled Pro-6C and
Pro+I-6C to virus-like particles (VLPs) to see if this would
further increase the immunogenicity of the chimeras. Both
Pro-6C and Pro+I-6C contained a SpyCatcher domain allowing
covalent coupling to SpyTag-decorated AP205 VLPs (25, 33).
Spy-Catcher Pro-6C and Pro+I-6C coupled to SpyTag VLPs
efficiently (Figure 4A) and properly folded Pf s48/45 epitope
I was retained during conjugation, as shown by western blot
and mAb45.1 sandwich ELISA (Figures 4A,B). Both VLPs
formed homogenous populations of non-aggregated antigen-
VLP complexes as demonstrated by transmission electron
microscopy (Figure 4C). Furthermore, the VLP-particles
displaying Pro-6C and Pro+I-6C demonstrated a low percentage
of polydispersity (<16%) measured by dynamic light scattering
(DLS) experiments and an average size of 71.8 and 73.7 nm,
respectively (Figure 4D).
Immunogenicity of Soluble and VLP-Based
Chimeric Constructs
The immunogenicity of soluble Pro-6C and Pro+I-6C, and of
Pro-6C and Pro+I-6C coupled to VLPs was assessed in vivo.
FIGURE 3 | Design and characterization of a multi-domain Pfs230-Pfs48/45 chimera. (A) Schematic representation of the Pro+I-6C chimera. This protein contains
the SpyCatcher sequence at the N-terminus and a His-tag at the C-terminus. 6-Cys domains are shown as boxes and numbers indicate the number of cysteines. The
Pro-domain does not contain cysteines. (B) Sandwich ELISA of purified chimera. Immune purified R0.6C was used as a reference. Size exclusion chromatography
analysis of (C) Pro-6C and (D) Pro+I-6C. SE-HPLC was performed under native conditions in a phosphate buffer of pH 7.2 to determine the amount of monomer in
the sample. The sizes (kDa) of the molecular mass markers are indicated.
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FIGURE 4 | Characterization of virus-like particle-based vaccines. SpyCatcher tagged Pro-6C and Pro+I-6C were mixed with SpyTag-AP205 resulting in a
unidirectional display of the chimeras on the VLP surface. (A) Reduced and non-reduced SDS-PAGE gel and western blot. The gels (left) are stained with coomassie
blue, while the western blots (right) are developed with mAb45.1 as primary antibody. The following was loaded corresponding to the numbers; Lane 1: AP205 (VLP);
lane 2: Pro-6C; lane 3: Pro-6C-VLP; lane 4: Pro+I-6C; Lane 5: Pro+I-6C-VLP. (B) Sandwich ELISA, using mAb 45.1 as the solid phase capture antibody.
(C) Transmission electron microscopy images (negative stain) of the VLP-based vaccines after assembly. Both Pro-6C-VLPs and Pro+I-6C-VLPs appear
non-aggregated, uniformly dispersed and have an estimated size of 30 nm. Scale bar 100 nm. (D) Dynamic light scattering (DLS) profile of the vaccine components
Pro-6C [10.5 nm, polydispersity (PD) 10.7%], Pro+I-6C (10.8 nm, PD 20.7%), VLP (25.6 nm, PD 16.8%) and the purified vaccine products; Pro-6C-VLP (71.8 nm, PD
11.5%), and Pro+I-6C-VLP (73.7 nm, PD 15.8%).
Groups of CD-1 mice (n = 8) were immunized 3 times at 3-
week intervals with equimolar amounts of antigen adjuvanted
on Alhydrogel R©. Soluble Pro+I-6C elicited significantly (Mann-
Whitney test, p = 0.0079) higher levels of Pf s230-specific
responses than soluble Pro-6C (Figure 5A). However, this
increase was not associated with higher levels of gametocyte-
specific antibodies (Figure 5C), possibly due to the difference
in Pfs230-specific antibody levels being masked by higher
6C-specific signals in the gametocyte ELISA, as observed
for single antigen constructs (Figure 2A). The functional
activity of pooled anti-sera from each group was then tested
at serial dilutions in the SMFA. Antibodies against soluble
Pro+I-6C promoted higher SMFA activity than antibodies
against Pro-6C at a 1/27 dilution (p < 0.001) (Figure 5D),
in line with the SMFA results obtained with the single
domain constructs (Figure 2D). VLP display did not provide
an increase in gametocyte-, Pf s48/45-, or Pf s230-specific
antibodies for both Pro-6C and Pro+I-6C (Figures 5A–C).
VLP-display of Pro-6C enhanced (Mann-Whitney test, p <
0.001) the production of functional antibodies as demonstrated
in the SMFA while there was no such effect for Pro+I-
6C (Figure 5D).
Functional Activity of Domain Specific
Antibodies in the SMFA
To investigate the functional activity of domain-specific
antibodies, pooled sera from mice immunized with soluble
Pro+I-6C (no VLP) were depleted for Pf s230- and Pf s48/45-
specific antibodies using affinity columns with immobilized
Pf s230 and Pf s48/45 respectively, as previously described for
human antibodies (13). Antibody depletion was confirmed
by ELISA (data not shown). The functional activity of
antibody-depleted sera was then tested in the SMFA in 2-
fold serial dilutions in the presence of complement. Sera
depleted of Pf s230-specific or Pf s48/45-specific antibodies
retained transmission blocking activity at 9- and 18-fold
dilutions, respectively, demonstrating that functional antibodies
against both proteins are induced by the Pro+I-6C construct
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FIGURE 5 | VLP-delivery of Pro-6C and Pro+I-6C. Groups of mice (n = 8) were immunized with soluble Pro-6C and Pro+I-6C or bound to AP205. Day 56 serum
was tested for antibody reactivity on ELISA plates coated with (A) Pfs230 Pro+I,II,III (B), Pfs48/45-6C or (C) gametocyte extract. Antibody titers (dots represents
individual mice) are expressed as EC50 values. Horizontal lines represent median values. The asterisks represent statistical significance determined by Mann-Whitney
test (**p < 0.01, ns not significant). (D) Functional activities of serial diluted sera were assessed in the SMFA. Transmission reducing activity (TRA) is the reduction of
oocyst load compared to a serum control. All samples are tested in the presence of active complement. Data points are best estimates of two independent SMFA
experiments and error bars represent 95% confidence intervals. Note that 1/81 and 1/247 samples were tested in SMFA only once and therefore no confidence
intervals are given. Comparison between samples was done using General Linear Mixed Regression analysis (***p < 0.005, ns, not significant).
(Figure 6A). Since the TB activity of Pf s230-specific antibodies
depends on complement (22), depleted anti-sera were re-
tested in SMFA with and without active complement. As
expected, Pf s230-specific antibodies (16C) lost their functional
activity in the absence of active complement (Figure 6B).
Since complement fixation is dependent on specific antibody
subclasses (34), we determined the IgG subclass profile
elicited by the Pro+I-6C formulation. The chimera elicited
predominantly IgG1 antibodies, and to a lower extent IgG2a
and IgG2b antibodies (Figure S1). Altogether, these data show
that functional antibodies are generated against both domains
of the chimeric construct and that Pf s230-specific antibodies are
complement dependent.
DISCUSSION
Pf s230 and Pf s48/45 are expressed during the P. falciparum
sexual stages in humans and elicit antibodies which effectively
prevent parasite multiplication in the infected mosquito (13).
Promising Pf s230- and Pf s48/45-based MTBV candidates are
currently entering clinical development individually. Here we set
out to produce constructs with higher potency and to this end
produced and tested chimeric proteins based on both vaccine
candidates. To the best of our knowledge, this is the first
study that explores a multivalent MTBV based on Pf s230 and
Pf s48/45. Our chimeric proteins induce antibodies that have
>80% transmission reducing activity in the SMFA, which is high
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FIGURE 6 | Functional activity of domain-specific antibodies generated by
Pro+I-6C. Domain-specific antibodies were depleted from pooled sera of mice
immunized with Pro+I-6C, using columns containing Pfs230-Pro+I and
Pfs48/45-10C (13), to generate sera that recognize either 6C or Pro+I
respectively. (A) Serial dilutions of sera containing Pro+I antibodies only (16C)
and sera containing 6C antibodies only (1Pro+I) were tested in the SMFA, in
the presence of active complement. (B) Total sera and sera containing Pro+I
antibodies only were re-tested with (+C) and without (no C) active
complement at a dilution of 1/9. Transmission reducing activity (TRA) is the
reduction of oocyst numbers compared to a serum control. Data points are
best estimates of two independent SMFA experiments and error bars
represent 95% confidence intervals.
enough to meet the no/go decision criterion for selection and
further vaccine development (35). Overall, our data show that
these chimeric proteins elicited antibodies with higher TB activity
in the SMFA than the single proteins alone (Figures 2D, 5D) and
are therefore attractive next generation vaccine candidates.
One concern when generating multivalent vaccines is that
one of the components is immunodominant and that responses
against the other component are therefore compromised (36,
37). To investigate this we tested specific antibody responses
against the individual domains by ELISA and demonstrated
that these are not affected when the domains are presented as
part of chimeric proteins. Moreover, the depletion experiments
showed that antibodies against the Pro+I- and 6C-domains
are functional in the SMFA. Interestingly, the Pro+I-6C
chimera elicited higher levels of functional Pf s230-specific
antibodies than the Pro+I domain alone; sera from Pro+I
immunized mice showed no TRA in the SMFA at 1/27
dilution, whereas sera depleted of 6C-specific antibodies from
mice immunized with Pro+I-6C still retained 99% TRA at
1/36 dilution. This apparent difference was not reflected in
levels of specific antibodies detected in the Pf s230-ELISA
indicating that functional activity in the SMFA is not only
dependent on quantity but also the quality of antibodies.
Importantly, there was no difference in levels of functional
antibodies against the Pf s48/45-6C-domain when comparing
Pro+I-6C and R0.6C immunized mice suggesting that the
increase in functional activity of Pf s230-specific antibodies
is, at least in part, related to a better presentation of
antibody epitopes in the Pf s230 domain I of the Pro+I-
6C chimera.
Adjuvants with the ability to enhance antigen immunogenicity
are critical components of an efficacious subunit vaccine. In
the case of chimeras that include Pf s230, it is particularly
important that vaccination elicit antibodies with complement-
fixing activity. Here we show that Pro+I-6C formulated on
Alhydrogel R© elicited high levels of IgG1 antibodies, but also
Pro+I specific IgG2a and IgG2b antibodies in mice. Murine
IgG2a and IgG2b are subclasses of IgG that bind with high affinity
to human complement (34). The activation of complement may
subsequently trigger lysis of gametes in the infected mosquito
(22). It remains to be determined whether the Pro+I-6C chimera
may also elicit complement-fixing antibodies in humans.
Both Pf s230- and Pf s48/45-based vaccine constructs are
rich in cysteine and proper disulfide bond formation is
critical for functional antibody responses (22, 38). Therefore,
successful construction and production of chimeric proteins
depend on the maintenance of conformational integrity of
immunologically relevant regions of the individual domains.
The mAb45.1 is a conformational mAb (2) that reacts with
properly folded Pf s48/45 but not disulphide reduced Pfs48/45
(38). Its reactivity with the fusion proteins indicate proper
cysteine connectivity of the Pf s48/45 domain. Accordingly,
our results from ELISA and immunoblotting analysis showed
that the purified chimeras expressed in L. lactis were strongly
recognized by mAb45.1 and had thus retained conformational
epitope I in the Pf s48/45-6C domain. It was particularly
encouraging that recombinant Pro+I-6C reacted with mAb45.1
since Pf s230 domain I contains four cysteine residues which
may potentially interfere with disulfide bonding of the Pf s48/45-
6C domain. While disulphide bond studies have not been
completed on the two chimera, the positive reactivity with
mAb45.1, indicate that the Pf s230 sequence does not disrupt
the proper disulphide formation of the Pf s48/45 6C domain
contained within. Correct folding was further supported by
antibody depletion experiments showing that both domains
of the chimeras elicited functional antibodies. The data thus
demonstrate that L. lactis is not only suitable for expression
of Pf s48/45 fragments (19), but also for Pf s230 fragments and
fusions thereof. The immune purification of the two chimeras
used here is not compliant with cGMP manufacturing since
a monoclonal antibody of rat origin was used. However, a
purification process based on conventional chromatographic
procedures is currently being developed. Although yields and
purity remain to be determined, it is likely that high product
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yields can be obtained through upscaling the fermentation
process which is straightforward since there is no requirement
for oxygen and vigorous stirring during fermentation (39).
Additionally, yields of properly folded protein speciesmay also be
increased through protein refolding processes as those developed
for R0.6C (20).
In conclusion, we have produced two chimeras composed
of leading vaccine candidates against the transmission stages of
P. falciparum. Both chimera elicited high levels of functional
antibodies in rodents and outperformed the corresponding
individual protein fragments. Previously, rodents have been
immunized with Pf s25 administered together with either Pf s28
or Pf s230C (40). In contrast to our findings for Pfs48/45-
Pfs230 chimeras, the Pf s25-based dual-antigen vaccines did
not elicit higher levels of functional antibodies than the
corresponding single antigen vaccines (40). Together these
data demonstrate that additive effects can only be achieved
for certain antigen combinations. Our results do not only
support the use of chimeric proteins for MTBV development
but also for malaria vaccine development in general (26, 28,
41, 42). Another advantage of multi-component vaccines is
that the production of antibodies against multiple antigens
might help reduce the spread of potential escape mutants
in the population. Such escape mutants may compromise
overall vaccine efficacy as exemplified with the RTS,S malaria
vaccine (43). This multivalent strategy is thus conceptually
attractive and will constitute a novel means toward control
and eventually eradication of malaria once clinical efficacy has
been demonstrated.
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Figure S1 | Subclass-specific antibody responses in mice immunized with
Pro+I-6C. Day 56 sera were tested for antibody reactivity on ELISA plates coated
(A) Pro+I or (B) 6C. Results for individual mice are shown, and a horizontal bar
represents each median value.
Figure S2 | Pre-immune mouse serum contains low intrinsic TRA. Pooled mouse
serum from each group was tested at 1/9 dilution in a single SMFA experiment.
TRA is the reduction of oocyst numbers compared to a serum control. Error bars
represent 95% confidence intervals. TRA values below 50% have large confidence
intervals and this can explain the observed variation between different groups. The
mean TRA of all groups is 21% (CIs: 5.7–34.1%) demonstrating that mouse serum
has low intrinsic TRA.
Table S1 | Production and quantification of Pfs230 and Pfs230/Pfs48/45
chimeric protein in L. lactis.
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